SANTEN PHARMACEUTICAL CO., LTD. (May 7, 2004) Code: 4536 URL http://www.santen.co.jp Financial Report for the Year Ended March 31, 2004 (Consolidated) Takakazu Morita, President and Chief Executive Officer Contact: Ichiro Otokozawa, Division Manager, Corporate Development and Administration Division Tel: 06-6321-7007

1. Performance for the year ended March 31, 2004

		(Figures are round	led down to the nea	arest million yen)
(1)	Operating results	Year to March 2004	Year to March 2003	% change 2004/2003
	Net sales (millions of yen)	89,857	90,252	(0.4%)
	Operating income (millions of yen)	14,525	12,697	14.4%
	Ordinary income (millions of yen)	15,790	12,899	22.4%
	Net income (millions of yen)	6,321	8,502	(25.7%)
	Net income per share (yen)	71.65	93.67	
	Diluted net income per share (yen)	71.64	85.97	
	Net income to shareholders' equity	6.3%	8.8%	
	Ordinary income to total assets	10.6%	8.6%	
	Ordinary income to net sales	17.6%	14.3%	

Note: ¹ Average number of shares outstanding March 31, 2004: 87,931,398

March 31, 2003: 90,452,016

 $^{\rm 2}\,{\rm One}$ change has been made in accounting policy.

(2)	Financial condition	March 31, 2004	March 31, 2003
	Total assets (millions of yen)	150,237	147,147
	Shareholders' equity (millions of yen)	103,499	97,125
	Shareholders' equity ratio	68.9%	66.0%
	Shareholders' equity per share (yen)	1,176.83	1,104.21

Note: ¹ Number of shares outstanding at end of period

March 31, 2004: 87,929,950

March 31, 2003: 87,932,738

Year to Year to (3) Cash flows March 2004 March 2003 Cash flows from operating activities (millions of yen) 23,196 15,807 Cash flows from investing activities (millions of yen) 5,246 (9,951)(12,122) Cash flows from financing activities (millions of yen) (6.507)Cash and cash equivalents at end of year (millions of yen) 41.422 25.053

(4) Consolidated subsidiaries and application of the equity method Number of consolidated subsidiaries: 12

Number of non-consolidated subsidiaries: 0 Number of affiliated company applied the equity method: 0

(5) Changes on consolidated subsidiaries and application of the equity method Number of consolidated subsidiaries: 0

Number of non-consolidated subsidiaries: 0 Number of affiliated company applied the equity method: 0

2. Forecasts of results for the year ending March 31, 2005

	Interim	Full year	
Net sales (millions of yen)	43,200	86,000	-
Operating income (millions of yen)	6,500	14,000	
Ordinary income (millions of yen)	6,400	13,800	
Net income (millions of yen)	3,500	8,000	
Reference: Expected net income per share (full-year basis)		90.98

Caution)

The aforementioned forecast in this brief financial report reflects the Company's current analysis of data available and the Company's assumption as of May 7, 2004. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's businesses; competitive pressures; changes in related laws and regulations; status of product development programs; and changes in exchange rates.

SANTEN PHARMACEUTICAL CO., LTD. (May 7, 2004) Code: 4536 URL http://www.santen.co.jp Financial Report for the Year Ended March 31, 2004 (Non-consolidated) Takakazu Morita, President and Chief Executive Officer Contact: Ichiro Otokozawa, Division Manager, Corporate Development and Administration Division Tel: 06-6321-7007

1. Performance for the year ended March 31, 2004

	(Figures are rounde	ed down to the nea	arest million yen)
		Year to	Year to	% change
(1)	Operating results	March 2004	March 2003	2004/2003
	Net sales (millions of yen)	80,227	82,372	(2.6%)
	Operating income (millions of yen)	17,469	17,329	0.8%
	Ordinary income (millions of yen)	18,680	17,011	9.8%
	Net income (millions of yen)	7,176	871	723.6%
	Net income per share (yen)	81.37	9.30	
	Diluted net income per share (yen)	81.36	—	
	Net income to shareholders' equity	6.9%	0.9%	
	Ordinary income to total assets	12.5%	11.1%	
	Ordinary income to net sales	23.3%	20.7%	

Note: ¹ Average number of shares outstanding

March 31, 2004: 87,931,398

March 31, 2003: 90,452,016

² One change has been made in accounting policy.

		Year to	Year to
(2)	Dividends	March 2004	March 2003
	Annual dividends per share (yen)	40.00	20.00
	Interim dividends per share (yen)	10.00	10.00
	End of period (yen)	30.00	10.00
	Total dividends paid (full-year) (millions of yen)	3,517	1,786
	Payout ratio	49.0%	215.1%
	Shareholders' equity yield	3.3%	1.8%

(3)	Financial condition	March 31, 2004	March 31, 2003
	Total assets (millions of yen)	150,240	147,869
	Shareholders' equity (millions of yen)	106,800	100,283
	Shareholders' equity ratio	71.1%	67.8%
	Shareholders' equity per share (yen)	1,214.37	1,140.12

Note: ¹ Number of shares outstanding at end of period March 31, 2004: 87,929,950 March 31, 2003: 87,932,738 ² Number of treasury stock at end of period March 31, 2004: 33,353 March 31, 2003: 2,771,565

2. Forecasts of results for the year ending March 31, 2005

	Interim	Full year
Net sales (millions of yen)	39,500	79,400
Operating income (millions of yen)	6,400	14,700
Ordinary income (millions of yen)	6,600	15,000
Net income (millions of yen)	3,800	9,200
Interim dividends per share (yen)	20.00	_
Dividends at end of period per share (yen)	_	20.00
Annual dividends per share (yen)	_	40.00
Reference: Expected net income per share (full	-year basis)	

Caution)

The aforementioned forecast in this brief financial report reflects the Company's current analysis of data available and the Company's assumption as of May 7, 2004. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's businesses; competitive pressures; changes in related laws and regulations; status of product development programs; and changes in exchange rates.